查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1691634

自然杀手(NK)细胞疗法的全球市场:临床试验，专利技术，共同研究，市场机会(2025年)

Global Natural Killer (NK) Cell Therapy Clinical Trials, Proprietary Technologies, Collaborations & Market Opportunity Insight 2025
出版日期: | 出版商: KuicK Research | 英文 320 Pages | 商品交期: 最快1-2个工作天内

价格

近年来，细胞疗法取得了巨大进步，改变了多种疾病的治疗方法。其中，NK（自然杀手）细胞疗法因其潜力而引起了人们的极大兴趣。最初，它主要用于癌症治疗，但现在也应用于自体免疫疾病等其他疾病。 NK 细胞在免疫系统对抗肿瘤和感染中发挥关键作用，研究人员正在努力增强其瞄准和摧毁有害细胞的自然能力。儘管该领域仍在发展中，许多治疗方法处于临床试验的早期阶段，但在创新研发和不断增加的研究资金的支持下，NK 细胞疗法的迅速兴起标誌着医疗保健领域的重大转变。

NK 细胞疗法最显着的发展之一是人们对同种异体 NK 细胞的兴趣日益浓厚。同种异体 NK 细胞可直接使用，源自于健康捐赠者，为大规模治疗提供可扩展的解决方案。这些治疗方法正在针对自体免疫疾病和癌症进行研究，反映出它们的应用范围正在扩大。例如，Nkarta 等公司正在推进针对重症肌无力（一种慢性自体免疫疾病）等疾病的同种异体 NK 细胞疗法，这表明 NK 细胞疗法有可能重塑癌症和自体免疫疾病的免疫疗法模式。同样，SMT Bio 的 SMT-NK 正在胆道癌领域进行评估。该疗法将帕博利珠单抗等免疫检查点抑制剂与NK细胞结合，以提高疗效，标誌着基于NK细胞的联合疗法取得了重要进展。

NK 细胞疗法的快速发展得到了私人投资者和政府机构的大力资金支持。例如，2024年末，Indapta Therapeutics获得2,250万美元资金，用于支持用于治疗癌症和自体免疫疾病的同种异体NK细胞疗法IDP-023的临床开发。这笔资金对于从正在进行的试验中产生数据以及进一步探索 NK 细胞疗法的潜力至关重要。同样，香港城市大学也获得了政府资助，用于开发CAR-NK细胞，以治疗一种罕见的儿科疾病——自体免疫性青少年皮肌炎。这些资金凸显了人们对 NK 细胞疗法日益增长的兴趣和投资，该疗法不仅用于治疗癌症，还用于治疗一系列其他免疫介导疾病。

总之，NK 细胞治疗市场即将迎来一段显着增长期，大量投资和技术进步将推动其进步。对同种异体 NK 细胞及其治疗癌症和自体免疫疾病的潜力的关注代表着免疫疗法的一个有希望的转变。策略合作、尖端技术和持续的资金流入可能会加速 NK 细胞疗法的发展，这可能会改变各种疾病的治疗模式。随着临床数据的出现，NK 细胞治疗市场预计将在未来的精准医疗中发挥关键作用，为传统疗法难以治疗的疾病提供新颖、直接的解决方案。

本报告提供全球自然杀手(NK)细胞疗法市场相关调查，提供市场概要，以及药物趋势，临床试验趋势，各地区趋势，及加入此市场的主要企业竞争情形等资讯。

目录

第1章 自然杀手(NK)细胞疗法的简介

第2章 NK细胞疗法的作用机制

  • NK细胞的细胞伤害作用
  • NK细胞疗法的工作
  • NK细胞疗法的方法

第3章 NK细胞疗法的治疗策略

  • NK细胞疗法单独疗法
  • 复式混合剂的NK细胞疗法

第4章 自然杀手(NK)细胞疗法的研究开发趋势(各适应症)

  • 癌症
    • 血液癌症
    • 固体癌
  • 自体免疫疾病及发炎性疾病
  • 微生物感染疾病
  • 神经退化性疾病

第5章 NK细胞疗法的特征强化方法

  • 奈米技术的利用
  • CAR的改造
  • CRISPR/Cas9遗传基因编辑的使用

第6章 世界自然杀手细胞疗法临床试验概要

  • 各国
  • 各适应症
  • 患者各市场区隔
  • 各期
  • 优先级

第7章 企业，适应症，各期的世界自然杀手细胞疗法临床试验

  • 研究
  • 前临床
  • 第0相
  • 第一阶段
  • 第一/二阶段
  • 第二阶段
  • 第二/三阶段

第8章 NK细胞疗法独自的方法和技术的洞察

  • 概要
  • 企业独自的技术

第9章 NK细胞疗法的伙伴关係与资金筹措

  • 最近的伙伴关係，合作，授权契约
  • 各企业资金筹措交易

第10章 FDA 指定的研究性 NK 细胞疗法

  • FDA简审类
  • FDA罕见疾病用医药品指定
  • 再生医疗尖端医疗指定

第11章 NK细胞疗法的市场趋势和临床试验预测

  • 目前市场趋势，开发，临床试验的评估
  • 未来的商业化的机会

第12章 竞争情形

  • Acepodia
  • Beijing JD Biotech
  • Cartherics
  • Catamaran Bio
  • Century Therapeutics
  • City of Hope National Medical Center
  • CRISPR Therapeutics
  • CytoImmune Therapeutics
  • Cytovia Therapeutics
  • Dragonfly Therapeutics
  • Editas Medicine
  • Fate Therapeutics
  • Gamida-Cell
  • GC Biopharma/GC Lab Cell
  • GICELL
  • Glycostem
  • HK inno.N
  • ImmunityBio
  • Karolinska Institute
  • Kiadis Pharma
  • Nkarta Therapeutics
  • NKGen Biotech
  • ONK Therapeutics
  • Sanofi
  • Senti Biosciences
  • Shoreline Biosciences
  • Sian Wuhan Medical Technology
  • Smart Immune
  • Sorrento Therapeutics
  • Therabest Korea
  • University of Texas M. D. Anderson Cancer Center
  • XNK Therapeutics
  • Zelluna Immunotherapy

Global Natural Killer (NK) Cell Therapy Clinical Trials, Proprietary Technologies, Collaborations & Market Opportunity Insight 2025 Report Highlights & Findings:

  • Global & Regional Market Trends By Indication
  • First NK Cell Therapy Approval Expected By 2028
  • Number Of NK Cell Therapies In Clinical Trials: >180 Therapies
  • Highest Phase For NK Cell Therapies Clinical Trials: Phase II/III
  • NK Cell Therapies Granted Fast Track & Orphan Status: > 5 Therapies
  • Global Natural Killer Cell Therapies Clinical Trials By Company

Indication & Phase

  • Insight On Recent Partnerships, Collaborations & Licensing Agreements
  • NK Cell Therapies Proprietary Technologies By Company
  • Monotherapy & Combinational Treatment Strategies

This Report Exclusively Examines Therapeutic Strategies That Employ Natural Killer (NK) Cells, Excluding Any Methods That Incorporate Antibody Engagers Intended To Bind To & Activate NK Cells.

Cell therapies have made significant progress in recent years, transforming treatment methods for a variety of diseases. Among these, NK (natural killer) cell therapies have gained considerable interest due to their potential. While they initially focused on cancer treatment, these therapies are now branching out to tackle non-cancerous conditions such as autoimmune diseases. NK cells play vital role in the immune system's fight against tumors and infections, and researchers are working to enhance their natural ability to target and destroy harmful cells. Although this field is still developing, with many therapies in early stages of clinical trials, the rapid enhancement of NK cell therapies, bolstered by innovative research and increasing funding, suggests a significant change in healthcare.

One of the most notable developments in NK cell therapies is the growing interest in allogeneic NK cells, which are derived from healthy donors and can be used off-the-shelf, offering a scalable solution for mass treatment. These therapies are being explored not only in cancer but also in autoimmune conditions, reflecting a broadening of their application. For example, companies like Nkarta are advancing allogeneic NK cell therapies for conditions such as myasthenia gravis, a chronic autoimmune disease, showing how NK cell therapy could potentially reshape the landscape of immunotherapy for both cancer and autoimmune disorders. Similarly, several companies are targeting specific cancers with engineered NK cells, such as SMT Bio's SMT-NK, which is being evaluated for biliary tract cancer. This therapy combines NK cells with immune checkpoint inhibitors like pembrolizumab to improve efficacy, marking a significant step forward in NK cell-based combination therapies.

The rapid advancement of NK cell therapies is being supported by robust funding from both private investors and government agencies. For instance, in late 2024, Indapta Therapeutics secured US$ 22.5 million in financing to support the clinical development of its allogeneic NK cell therapy, IDP-023, for cancer and autoimmune diseases. This influx of capital is crucial for generating data in ongoing trials, allowing for further exploration of NK cell therapy's potential. Similarly, the City University of Hong Kong received a government grant to develop CAR-NK cells for treating autoimmune juvenile dermatomyositis, a rare pediatric disease. This funding highlights the increasing interest and investment in NK cell therapies not just for cancer but also for a range of other immune-mediated conditions.

At the same time, collaborations between biotechnology firms and pharmaceutical giants are helping to drive clinical development. For example, Indapta Therapeutics partnered with Sanofi to explore the combination of IDP-023 with Sarclisa (isatuximab) for multiple myeloma. This collaboration underscores the importance of integrating NK cell therapies with other established treatments to enhance their effectiveness. By combining NK cells with existing monoclonal antibodies or chemotherapy regimens, these treatments could overcome some of the limitations seen with monotherapies. Additionally, innovative technologies such as nanomaterials and gene editing are being incorporated into NK cell therapy to enhance targeting precision and improve clinical outcomes. Nanoparticles are being used to stabilize NK cells and boost their ability to reach and eliminate tumor cells, offering an exciting new approach to improving the performance of these therapies.

To conclude, the NK cell therapy market is entering a period of significant growth, with substantial investments and technological advancements driving progress. The focus on allogeneic NK cells and their potential for treating both cancer and autoimmune diseases represents a promising shift in immunotherapy. Strategic collaborations, cutting-edge technologies, and the continued influx of funding will likely accelerate the development of NK cell therapies, transforming the treatment paradigm for a wide array of diseases. As clinical data continues to emerge, the NK cell therapy market is poised to play a pivotal role in the future of precision medicine, offering novel, off-the-shelf solutions for conditions that have historically been difficult to treat with conventional therapies.

Table of Contents

1. Introduction to Natural Killer (NK) Cell Therapy

2. Mechanism Of Action of NK Cell Therapy

  • 2.1 Cytotoxic Action Of NK Cells
  • 2.2 Working Of NK Cell Therapy
  • 2.3 NK Cell Therapies Approaches
    • 2.3.1 CAR NK Cell Therapies
    • 2.3.2 TCR NK Cell Therapies

3. Treatment Strategies For NK Cell Therapies

  • 3.1 NK Cell Therapy As Monotherapy
  • 3.2 NK Cell Therapy As Combinatorial Agent

4. Natural Killer (NK) Cell Therapy Research & Development Trends By Indication

  • 4.1 Cancer
    • 4.1.1 Hematological Cancers
    • 4.1.2 Solid Cancers
  • 4.2 Autoimmune & Inflammatory Disorders
  • 4.3 Microbial Infections
  • 4.4 Neurodegenerative Diseases

5. NK Cell Therapy Characteristics Enhancement Approaches

  • 5.1 Use Of Nanotechnology
  • 5.2 Modifications In CARs
  • 5.3 Use Of CRISPR/Cas9 Gene Editing

6. Global Natural Killer Cell Therapies Clinical Trials Overview

  • 6.1 By Country
  • 6.2 By Indication
  • 6.3 By Patient Segment
  • 6.4 By Phase
  • 6.5 By Priority Status

7. Global Natural Killer Cell Therapies Clinical Trials By Company, Indication & Phase

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Phase-0
  • 7.4 Phase-I
  • 7.5 Phase-I/II
  • 7.6 Phase-II
  • 7.7 Phase-II/III

8. NK Cell Based Therapy Proprietary Approaches & Technologies Insight

  • 8.1 Overview
  • 8.2 Proprietary Technologies By Company

9. Partnerships & Funding for NK Cell Therapies

  • 9.1 Recent Partnerships, Collaborations & Licensing Agreements
  • 9.2 Funding Deals By Companies

10. Investigational NK Cell Therapies With FDA Designations

  • 10.1 FDA Fast Track Designation
  • 10.2 FDA Orphan Drug Designation
  • 10.3 Regenerative Medicine Advanced Therapy Designation

11. NK Cell Therapies Market Trends & Clinical Trials Outlook

  • 11.1 Current Market Trends, Developments & Clinical Trials Assessment
  • 11.2 Future Commercialization Opportunity

12. Competitive Landscape

  • 12.1 Acepodia
  • 12.2 Beijing JD Biotech
  • 12.3 Cartherics
  • 12.4 Catamaran Bio
  • 12.5 Century Therapeutics
  • 12.6 City of Hope National Medical Center
  • 12.7 CRISPR Therapeutics
  • 12.8 CytoImmune Therapeutics
  • 12.9 Cytovia Therapeutics
  • 12.10 Dragonfly Therapeutics
  • 12.11 Editas Medicine
  • 12.12 Fate Therapeutics
  • 12.13 Gamida-Cell
  • 12.14 GC Biopharma/GC Lab Cell
  • 12.15 GICELL
  • 12.16 Glycostem
  • 12.17 HK inno.N
  • 12.18 ImmunityBio
  • 12.19 Karolinska Institute
  • 12.20 Kiadis Pharma
  • 12.21 Nkarta Therapeutics
  • 12.22 NKGen Biotech
  • 12.23 ONK Therapeutics
  • 12.24 Sanofi
  • 12.25 Senti Biosciences
  • 12.26 Shoreline Biosciences
  • 12.27 Sian Wuhan Medical Technology
  • 12.28 Smart Immune
  • 12.29 Sorrento Therapeutics
  • 12.30 Therabest Korea
  • 12.31 University of Texas M. D. Anderson Cancer Center
  • 12.32 XNK Therapeutics
  • 12.33 Zelluna Immunotherapy

List of Figures

  • Figure 1-1: NK Cells - Identification & Discovery Timeline
  • Figure 1-2: NK Cell Subsets - CD56low/dim v/s CD56bright
  • Figure 2-1: Cytotoxic Action Of NK Cells
  • Figure 2-2: CAR-NK Cells Preparation
  • Figure 2-3: Delivery Of CAR Gene Into NK Cell
  • Figure 2-4: NK Cells Sources For Therapy
  • Figure 2-5: Structure Of CAR/TCR-NK Cell
  • Figure 4-1: PRAME-TCR-NK Cells Therapy Phase 1/2 (NCT06383572) Study - Initiation & Completion Year
  • Figure 4-2: GCC2005A-P101 Phase 1 (NCT06699771) Study - Initiation & Completion Year
  • Figure 4-3: QUILT-106 Phase 1 (NCT06334991) Study - Initiation & Completion Year
  • Figure 4-4: TAK-007-2001 Phase 2 (NCT05020015) Study - Initiation & Completion Year
  • Figure 4-5: Indapta-Trial-1 Phase 1/2 (NCT06119685) Study - Initiation & Completion Year
  • Figure 4-6: PRAMETIME-Mel Phase 1 (NCT06660420) Study - Initiation & Completion Year
  • Figure 4-7: Ntrust-1 Phase 1 (NCT06557265) Study - Initiation & Completion Year
  • Figure 4-8: Ntrust-2 Phase 1 (NCT06733935) Study - Initiation & Completion Year
  • Figure 4-9: IDP023-2-101 Phase 1 (NCT06677710) Study - Initiation & Completion Year
  • Figure 4-10: CALiPSO-1 Phase 1 (NCT06255028) Study - Initiation & Completion Year
  • Figure 5-1: Improvements In NK Cell Therapy Using Nanotechnology
  • Figure 5-2: Basic Structure Of CARs On NK Cell
  • Figure 5-3: Gene Editing Tools
  • Figure 6-1: Global - NK Cell Therapies Clinical Trials By Country, 2025
  • Figure 6-2: Global - NK Cell Therapies Clinical Trials By Indication, 2025
  • Figure 6-3: Global - NK Cell Therapies Clinical Trials By Patient Segment, 2025
  • Figure 6-4: Global - NK Cell Therapies Clinical Trials By Phase, 2025
  • Figure 6-5: Global - NK Cell Therapies Clinical Trials By Priority Status, 2025
  • Figure 8-1: Artiva Biotherapeutics - Proprietary CAR-NK Cell Platform
  • Figure 8-2: Artiva Biotherapeutics - Proprietary AlloNKTM NK Cell Therapy Scaling Platform
  • Figure 8-3: Catamaran Bio - Proprietary Tailwind(R) Platform
  • Figure 8-4: Cellularity - CYNK-CARs
  • Figure 8-5: GAIA BioMedicine - Proprietary NK Cell Therapy Working Mechanism
  • Figure 8-6: GAIA BioMedicine - Proprietary Technologies' Salient Features
  • Figure 8-7: Gamida Cell - NK Cell Therapy Manufacturing Process
  • Figure 8-8: HebeCell - Proprietary Scalable NK Cell Technology
  • Figure 8-9: ImmunityBio - Proprietary haNK(R) Cell Structure
  • Figure 8-10: Nkarta - Proprietary CAR-NK Cell Structure
  • Figure 8-11: Nkarta - Proprietary NK Cell Therapy Platform
  • Figure 8-12: Senti Biosciences - Gene Circuit Technology Platform
  • Figure 8-13: Senti Biosciences - Gene Circuit Technology Platform Applicability
  • Figure 8-14: Wugen - Proprietary Memory NK Cell Platform

List of Tables

  • Table 10-1: Investigational NK Cell Therapies With Fast Track Designation
  • Table 10-2: Investigational NK Cell Therapies With Orphan Drug Designation
  • Table 10-3: Investigational NK Cell Therapies With Regenerative Medicine Advanced Therapy Designation